Pulsed Radiofrequency Treatment (pRF): A Modern Option for Treating Chronic Pain
Pulsed Radiofrequency Treatment (pRF) is a minimally invasive, non-destructive method for treating chronic pain. Unlike thermal radiofrequency ablation, which uses heat to cauterize nerves and block their function, pRF aims to modulate pain transmission through electric fields without causing permanent tissue damage.
In pRF, a probe is placed near the affected nerve under image guidance (e.g., ultrasound or X-ray). Through this probe, high-frequency electrical impulses (typically 400–500 kHz) are delivered in short pulses, heating the tissue to a maximum of 42 °C. This temperature is sufficient to influence the electrical activity of the nerve cells without destroying them.
The exact mechanism of action is not yet fully understood; however, studies suggest that pRF reduces the activity of microglia in the spinal cord and inhibits proinflammatory cytokines such as interleukin-6 and TNF-α, which contributes to pain relief. Ultimately, this modulates the immune system and reduces oxidative stress experienced by the nerve cells.
pRF is primarily used for neuropathic pain, especially when the pain can be traced to specific nerves or nerve roots. Common indications include:
Radiculopathies
Peripheral neuropathic pain due to nerve lesions, including post-herpetic neuralgia
Trigeminal neuralgia (*Not applied at the ISSZ)
Before performing pRF, diagnostic nerve blocks using local anesthetics are carried out to identify the source of pain and to assess the likelihood of therapeutic success.
The treatment is performed on an outpatient basis under local anesthesia. After positioning the probe, the target nerve is electrically stimulated to confirm accurate placement—a process known as sensory testing. The pRF is then applied for a specific duration, usually several minutes. Patients typically experience the procedure as painless or only mildly uncomfortable. In most cases, two sessions are carried out, spaced 2–3 weeks apart, to enhance the therapeutic effect.
Pain relief following pRF can vary from person to person. Many patients report symptom improvement lasting several months, on average around 3 to 6 months. In some cases, the effect may last even longer. If the pain returns, the treatment can be repeated.
- Minimally invasive and can be performed on an outpatient basis
- No permanent nerve damage
- Suitable for patients who cannot or do not wish to receive corticosteroids
- Low risk of side effects
The goal of the treatment is to resume physical activity during the pain-reduced or pain-free period, thereby improving physical—and especially psychological—well-being.
Pulsed radiofrequency treatment offers an effective and gentle alternative for managing chronic neuropathic pain syndromes. Due to its non-destructive mechanism of action and the possibility of repetition, it represents a valuable addition to the therapeutic spectrum.
Subscribe to Newsletter
We’d be happy to share more about us and our services in the next newsletter and on www.issz.ch.
Current Affairs
Further News & Publications
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Suzetrigin: A Novel Pain Medication in Switzerland
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to
1 year of Interventional Pain Medicine SZ AG – Less pain, more quality of life
On 3 May 2025, we celebrated the one-year anniversary of the Institute for Interventional Pain Medicine SZ AG – a significant milestone on our journey
Neuromodulation: Innovative Approaches to Chronic Pain
The term neuromodulation encompasses a variety of established therapeutic methods, including not only spinal epidural neurostimulation (Spinal Cord Stimulation – SCS), which is often used
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Suzetrigin: A Novel Pain Medication in Switzerland
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to
Pulsed Radiofrequency Treatment (pRF)
Die gepulste Radiofrequenz-Behandlung (pRF) stellt eine minimalinvasive, nicht-destruktive Methode zur Behandlung
chronischer Schmerzen dar. Im Gegensatz zur thermischen Radiofrequenzablation, die durch Hitzeeinwirkung Nerven
1 year of Interventional Pain Medicine SZ AG – Less pain, more quality of life
On 3 May 2025, we celebrated the one-year anniversary of the Institute for Interventional Pain Medicine SZ AG – a significant milestone on our journey